Literature DB >> 31242371

Immune Checkpoint Blockade plus Axitinib for Renal-Cell Carcinoma. Reply.

Brian I Rini1, Thomas Powles2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31242371     DOI： 10.1056/NEJMc1905518

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  4 in total

1.  Prognosis of Japanese metastatic renal cell carcinoma patients in the targeted therapy era.

Authors:  Sei Naito; Tomoyuki Kato; Kazuyuki Numakura; Shingo Hatakeyama; Tomoyuki Koguchi; Shuya Kandori; Yoshihide Kawasaki; Hisanobu Adachi; Renpei Kato; Shintaro Narita; Hayato Yamamoto; Soichiro Ogawa; Sadafumi Kawamura; Wataru Obara; Akihiro Ito; Hiroyuki Nishiyama; Yoshiyuki Kojima; Chikara Ohyama; Tomonori Habuchi; Norihiko Tsuchiya
Journal:  Int J Clin Oncol       Date:  2021-06-30       Impact factor: 3.402

Review 2.  Natural history of untreated kidney cancer.

Authors:  Kristen McAlpine; Antonio Finelli
Journal:  World J Urol       Date:  2021-02-16       Impact factor: 4.226

3.  [Stereotactic body radiotherapy as "first-line treatment" for oligometastatic renal cell cancer].

Authors:  Matthias Guckenberger
Journal:  Strahlenther Onkol       Date:  2022-03-12       Impact factor: 3.621

4.  Impact of the COVID-19 Pandemic on the Urologist's clinical practice in Brazil: a management guideline proposal for low- and middle-income countries during the crisis period.

Authors:  Arie Carneiro; Marcelo Langer Wroclawski; Bruno Nahar; Andrey Soares; Ana Paula Cardoso; Nam Jin Kim; Fabricio Torres Carvalho
Journal:  Int Braz J Urol       Date:  2020 Jul-Aug       Impact factor: 1.541
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.